Omega Fund Management’s enGene Therapeutics ENGN Stock Holding History

Omega Fund Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Hold	876,357	–	–	0.82%	9
2026 Q1	$5.97M	Hold	876,357	–	–	3.66%	6
2025 Q4	$7.91M	Buy	876,357 +350,000	+66%	+$2.8M	2.76%	7
2025 Q3	$3.6M	Hold	526,357	–	–	1.62%	8
2025 Q2	$1.92M	Hold	526,357	–	–	1.24%	11
2025 Q1	$2.36M	Hold	526,357	–	–	1.39%	10
2024 Q4	$3.5M	Sell	526,357 -550,000	-51%	-$4.27M	2.27%	8
2024 Q3	$7.1M	Hold	1,076,357	–	–	4.44%	5
2024 Q2	$10.2M	Hold	1,076,357	–	–	7.52%	4
2024 Q1	$18.2M	Sell	1,076,357 -54,818	-5%	-$671K	11.77%	4
2023 Q4	$10.4M	Buy	+1,131,175	New	+$10M	8.46%	4

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Omega Fund Management's ENGN Position: Q2 2026 in Review

Omega Fund Management held its enGene Therapeutics (ENGN) position steady in Q2 2026 at 876,357 shares worth $1.52M. The position accounts for 0.82% of the portfolio, ranked #9.

Omega Fund Management first reported a position in ENGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $18.2M in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Omega Fund Management held 876,357 shares of enGene Therapeutics worth $1.52M as of Q2 2026.
Omega Fund Management left its enGene Therapeutics share count unchanged in Q2 2026.
enGene Therapeutics made up 0.82% of Omega Fund Management's portfolio in Q2 2026, its #9 holding.
Omega Fund Management first reported a position in enGene Therapeutics in Q4 2023 and has held it in 11 quarters since.
Omega Fund Management's enGene Therapeutics position peaked at $18.2M in Q1 2024.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Omega Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.